My peer-based valuation of Bisantrene.
Pillar 1 - Trodelvy - Bisantrene Comparison.pdf
This valutation is reinforced by a comparison done to the 2020 buyout of Immunomedics by Gilead for USD $21B. I recognise the limitations of comparing a company that has achieved a recent FDA approval with RAC, a company that is in the preclinical stages of understanding the potential for Bisantrene as an FTO inhibitor. However, I believe that because RAC and Bisantrene have the avantage of historic FDA approval in France and a massive set of phase I, II, and III historical data, it positions them at enough of a distance from preclinical stage to make the comparison more logical and realistic. Within the PDF you will discover that Trodelvy is a suitable molecule to compare to based on the target protein expression in multiple cancer types, potential drug synergies, breast cancer market, and singular FDA approval.
Highlights of the PDF include:
- FTO has been established as a significant prognostic marker in more cancer types than Trop-2 (22 to 13)
- Bisantrene has potentially more opportunity for cancer therapy synergy than Trodelvy through the FTO mechanism (6 to 5)
- Bisantrene has the potential to address at least 60% of the breast cancer market, which is three to four times more than Trodelvy currently (15-20%).
- Both drugs have received one FDA approval
- Clear demonstration of value and potential of a potent FTO inhibitor, like Bisantrene, when compared to Trodelvy
I estimate the value of bisantrene at above $100 per share, provided RAC can realise the true clinical potential of bisantrene as an anti-cancer agent as well as an FTO inhibitor.
This information has been gathered to my best knowledge and undertanding, which may be incorrect and/or inconsistent.
All IMO - DYOR
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO (new thread)
Pillar 1 - FTO (new thread), page-427
-
- There are more pages in this discussion • 2,563 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.57 |
Change
-0.035(2.18%) |
Mkt cap ! $272.6M |
Open | High | Low | Value | Volume |
$1.69 | $1.69 | $1.55 | $435.0K | 270.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | $1.57 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.59 | 1100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1104 | 1.565 |
2 | 2875 | 1.560 |
2 | 2782 | 1.555 |
3 | 3669 | 1.550 |
2 | 2400 | 1.540 |
Price($) | Vol. | No. |
---|---|---|
1.580 | 5247 | 1 |
1.585 | 2600 | 2 |
1.590 | 1361 | 1 |
1.595 | 550 | 1 |
1.620 | 2815 | 1 |
Last trade - 14.26pm 30/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online